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The incidence and risk factors for acute cholecystitis after allogeneic hematopoietic stem cell transplantation
(HSCT) are not well deﬁned. Of 644 consecutive adult transplants performed at our institution between 2001
and 2011, acute cholecystitis occurred in the ﬁrst year of transplant in 32 patients (5.0%). We conducted 2
retrospective case-control studies of this population to determine risk factors for cholecystitis after HSCT and
to evaluate the performance of different methods of imaging to diagnosis cholecystitis in patients undergoing
HSCT compared with non-HSCT patients. In the HSCT population, development of cholecystitis was associated
with an increased 1-year overall mortality rate (62.5% versus 19.8%, P < .001). The risk of developing
cholecystitis was higher in patients who received total parenteral nutrition (TPN) (adjusted odds ratio, 3.41;
P ¼ .009). There was a trend toward more equivocal abdominal ultrasound ﬁndings in HSCT recipients with
acute cholecystitis compared with nontransplant patients (50.0% versus 30.6%, P ¼ .06). However, hep-
atobiliary iminodiacetic acid (HIDA) scans were deﬁnitively positive for acute cholecystitis in most patients in
both populations (80.0% of HSCT recipients versus 77.4% of control subjects, P ¼ .82). In conclusion, acute
cholecystitis is a common early complication of HSCT, the risk is increased in patients who receive TPN, and it
is associated with high 1-year mortality. In HSCT recipients with ﬁndings suggestive of acute cholecystitis,
especially those receiving TPN, early use of HIDA scan may be considered over ultrasound.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Patients who undergo allogeneic hematopoietic stem cell
transplantation (HSCT) are susceptible to infections, leading
to increased morbidity and mortality [1,2]. One infectious
complication of HSCT is acute cholecystitis, a condition
characterized by inﬂammation of the gallbladder with or
without gallstone obstruction in the cystic duct [3]. Although
biliary sludge formation [4-6] and cholelithiasis [5,7,8] are
known to occur in HSCT patients, the incidence of acute
cholecystitis and its risk factors in this population are not
well described [9-12].
Prompt recognition of acute cholecystitis is critical in both
immunocompetent and immunosuppressed patients.edgments on page 771.
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14.12.005However, the diagnosis of acute cholecystitis is often delayed
in the HSCT population, because transplant patients are
prone to multiple hepatobiliary complications that have
similar clinical presentations and the typical signs of
inﬂammation/infection may be masked by immune and
marrow suppression [5]. In the present study, we reviewed
644 consecutive patients undergoing HSCT to identify pa-
tients who experienced acute cholecystitis. We subsequently
performed 2 separate retrospective case-control analyses:
the ﬁrst to deﬁne the risk factors for development of acute
cholecystitis after HSCT and the second to determine the
diagnostic utility of radiographic modalities at presentation
of this disease in the transplant population.METHODS
Study Population
Between January 2001 and December 2011, 644 patients underwent
allogeneic HSCT at the Hospital of the University of Pennsylvania. Medical
records of these patients were screened for International Classiﬁcation of
Table 1
Baseline Demographic and Clinical Characteristics
Demographic
Characteristic
HSCT Acute
Cholecystitis
Patients
(n ¼ 32)
HSCT Non-
Cholecystitis
Control
Subjects
(n ¼ 96)
Non-HSCT
Cholecystitis
Control
Subjects
(n ¼ 96)
P
Median age at
HSCT, yr (range)
52.2 (24-75) 52.0 (20-76) 52.5 (18-78)
Men 21 (65.6) 63 (65.6) 63 (65.6)
Women 11 (34.3) 33 (34.4) 33 (34.4)
Underlying disease
ALL 5 (15.6) 11 (11.5) .971
AML 13 (40.6) 39 (40.6) .442
CLL/lymphoma 4 (12.5) 16 (16.7) 1
MDS 3 (9.4) 11 (11.5) .532
MM 2 (6.3) 8 (8.3) .420
PMF 3 (9.4) 3 (3.1) 1
CML 2 (6.3) 4 (4.2) .144
Other 0 4 (4.2) .926
Graft source
Bone marrow 6 (18.8) 28 (29.2) .283
Peripheral blood 26 (81.2) 68 (70.8)
Sibling donor 15 (46.9) 53 (55.2) .414
Conditioning regimen
TBI-containing 14 (43.8) 43 (44.8) .918
Myeloablative 18 (56.2) 53 (55.2) .919
Reduced intensity 14 (43.8) 43 (44.8)
ABO compatible graft 21 (67.7) 46 (49.0) .162
GVHD prophylaxis
Tac containing 23 (71.9) 70 (72.9) .909
Tac/MTX 19 (59.4) 57 (59.3)
Tac/MTX/
maraviroc
4 (12.5) 13 (13.5)
CsA/MTX 6 (18.8) 15 (15.6)
CsA/steroids 1 (3.1) 3 (3.1)
CsA/mycophenolate 1 (3.1) 7 (7.3)
None 1 (3.1) 1 (1.0)
TPN 20 (64.5) 37 (39.8) .019
CMV reactivation 5 (15.6) 22 (23.3) .371
Weight loss >10% 13 (46.4) 38 (42.3) .489
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leu-
kemia; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syn-
drome; MM, multiple myeloma; PMF, primary myeloﬁbrosis; CML, chronic
myelogenous leukemia; TBI, total body irradiation; tac, tacrolimus; MTX,
methotrexate; CsA, cyclosporine.
Values are number of cases with percents in parentheses, unless otherwise
indicated.
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all conditions related to acute cholecystitis, including gallbladder calculus,
bile duct calculus, chronic cholecystitis, perforation or obstruction of gall-
bladder, cholecystectomy, and cholecystostomy. Detection of 1 or more of
these conditions after the date of transplantation triggered a manual chart
review to conﬁrm cases of acute cholecystitis in the ﬁrst year after HSCT.
Cases were deﬁned as (1) having 1 imaging modality interpreted by a
radiologist as deﬁnitively positive for acute cholecystitis, including
abdominal ultrasound (US), abdominal computed tomography (CT), or
hepatobiliary iminodiacetic acid (HIDA) scan, or (2) having surgical gall-
bladder pathology consistent with acute cholecystitis. Patients with an ICD-
9 code related to acute cholecystitis but without 1 of the 2 above inclusion
criteria were excluded. The institutional review board approved this study.
Data Collection and Study Design
To identify risk factors for development of acute cholecystitis, we con-
ducted a nested case-control analysis with control subjects randomly
selected through incidence density sampling of the institutional transplant
cohort (N ¼ 644) and assigned to cases at a rate of 3:1, matching for age and
sex. We then evaluated multiple potential risk factors for the development
of acute cholecystitis, including type of underlying hematologic malignancy,
graft source, donor type, ABO incompatibility, conditioning intensity, con-
ditioning regimen containing versus not containing total body irradiation,
graft-versus-host disease (GVHD) prophylaxis regimen, weight loss >10%
compared with day þ0 body weight, any total parenteral nutrition (TPN)
use, and cytomegalovirus (CMV) reactivation, the latter deﬁned as serum
PCR positivity. Cases were counted as having 1 of the above risk factors if
present before diagnosis of acute cholecystitis, whereas control subjectswere counted as having a risk factor if present within the ﬁrst year of
transplant. In an exploratory analysis, we also compared the 1-year survival
rate of cases and control subjects using a chi-square test.
In a second, separate case-control analysis, we compared the radio-
graphic ﬁndings of US, CT scan, and HIDA scan in HSCT recipients (n ¼ 32)
versus non-transplant control subjects (n ¼ 96) diagnosed with acute
cholecystitis at our institution. Nontransplant control subjects were
randomly selected from our institution’s medical record system by
screening for ICD-9 diagnostic codes for ‘acute cholecystitis’ and all condi-
tions related to acute cholecystitis, including gallbladder calculus, bile duct
calculus, chronic cholecystitis, perforation or obstruction of gallbladder,
cholecystectomy, and cholecystostomy, entered between 2001 and 2011. As
in the ﬁrst case-control study, cases of acute cholecystitis were conﬁrmed
through manual chart review. Control subjects were assigned to cases at a
rate of 3:1 and matched for age and sex. In these 2 populations, we
compared the number of abdominal US, CT, and HIDA scans performed and
the proportion of these radiographic studies interpreted by an attending
radiologist as positive, negative, or equivocal for acute cholecystitis. Positive
studies were those in which acute cholecystitis was stated by the inter-
preting radiologist as the ﬁnal diagnosis, and negative studies were those in
which a normal gallbladder was seen or therewere no radiographic ﬁndings
of acute cholecystitis. Equivocal studies were those in which a deﬁnitive
radiographic diagnosis was not made. In these equivocal studies, a differ-
ential diagnosis was provided with acute cholecystitis as one of several
diagnostic considerations, or, alternatively, the radiologist stated that the
diagnosis of acute cholecystitis was equivocal.Statistical Analysis
Cases and control subjects were compared with chi-square or Fisher’s
exact tests as appropriate. P < .05 was accepted as statistically signiﬁcant.
Logistic regression analysis was used to adjust for covariates when assessing
risk factors for development of acute cholecystitis.RESULTS
In our transplant cohort of 644 patients (630 ﬁrst trans-
plants, 13 second transplants, and 1 third transplant), 32
patients (5.0%) had radiographic and/or pathologic evidence
of acute cholecystitis in the ﬁrst year after HSCT and were
counted as “case” patients. Baseline characteristics of these
patients and each of the 2 control groups are listed in Table 1.
For each of these characteristics, data were successfully
collected for all patients with the following exceptions: post-
transplant weights were unavailable for 10 patients (4 cases,
6 control subjects), ABO incompatibility status was unavai-
lable for 1 patient (case), CMV reactivation was unavailable
for 1 patient (control), and TPN use was unavailable for 4
patients (1 case, 3 control subjects). Patients had a mean age
of 52 years, and most (65.6%) were men. There were no
signiﬁcant baseline differences between cases and transplant
control subjects with regard to underlying hematologic
malignancy, graft source, donor type, conditioning regimen,
ABO incompatibility, GHVD prophylaxis regimen, CMV
reactivation, or weight loss after transplant.
Of those patients who developed acute cholecystitis in the
ﬁrst year after HSCT, the median time between day of trans-
plantation and diagnosis of acute cholecystitis was 56.5 days
(range, 6 to 342). Of note, 21 of 32 cases (65.6%) occurred
within 90 days of transplant. Twelve patients (37.5%) were
conﬁrmed as having acute cholecystitis by positive imaging
alone (none of these patients underwent cholecystectomy), 4
cases (12.5%) were conﬁrmed by pathology but had negative
or equivocal imaging studies (these patients ultimately went
to surgery based on high clinical suspicion), and 16 (50%) had
both imaging and pathology that were consistent with
cholecystitis. As detected by pathology and/or imaging, 21
patients (65.6%) had acalculous cholecystitis, whereas the
other 11 (34.4%) had evidence of cholelithiasis. Twenty cases
of acute cholecystitis (62.5%) were treated with cholecystec-
tomy, whereas 7 (21.9%) underwent cholecystostomy tube
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biotics and supportive care.
Post-transplant cholecystitis was associated with poor
survival outcomes. In an exploratory analysis, overall mor-
tality at 1 year after HSCT was signiﬁcantly higher in acute
cholecystitis case patients compared with control subjects
(62.5% versus 19.8%, P < .001). Of the 20 acute cholecystitis
patients who died within 1 year of transplant, 3 (15.0%) died
as a direct result of acute cholecystitis; septic shock was the
immediate cause of death in all 3 cases. One of these pa-
tients developed acute cholecystitis and subsequent septic
shock approximately 6 months after transplant in the
setting of graft failure. The other 2 patients developed acute
cholecystitis and septic shock before neutrophil engraft-
ment. The time between diagnosis of acute cholecystitis and
death for each of these patients was 6, 3, and 19 days,
respectively. In all 3 patients who died, acute cholecystitis
was managed by placement of a cholecystostomy tube.
Univariate analysis revealed that TPN use was signiﬁ-
cantly associated with the development of acute cholecys-
titis. A backward elimination model including all covariates
used in the univariate analysis was created, but only TPN
remained signiﬁcant in the multivariate analysis (adjusted
odds ratio, 3.41; P ¼ .009). Among patients who were given
TPN and developed acute cholecystitis, median time be-
tween last TPN use and diagnosis of cholecystitis was 3.5
days (range, 0 to 60) and median duration of TPN use was 7.5
days (range, 2 to 60). No signiﬁcant associations were found
with regard to underlying malignancy, graft source, donor
type, ABO incompatibility, conditioning regimen, GVHD
prophylaxis regimen, CMV reactivation, or weight loss.
In the second case-control study, HSCT recipients with
acute cholecystitis underwent abdominal USmore frequently
than nontransplant acute cholecystitis patients (93.8% versus
75.0%, P ¼ .02). CT and HIDA scans were performed at similar
rates in both populations (CT: 53.1% versus 55.2%, P ¼ .85;
HIDA: 46.9% versus 32.3%, P¼ .14). Therewas a trend toward a
higher frequency of equivocal US studies (as opposed to
deﬁnitively positive or negative for acute cholecystitis) in the
HSCT population compared with the nontransplant control
subjects (50.0% versus 30.6%, P ¼ .06). CT was equivocal for
acute cholecystitis in47.1%ofHSCTpatients and in37.7%of the
general population control patients (P¼ .37). HIDA scanswere
not interpreted as equivocal in any patient in either popula-
tion. In addition, HIDA was deﬁnitively positive for acute
cholecystitis in a high proportion of patients in both pop-
ulations (80.0% of HSCT recipients versus 77.4% of control
patients, P ¼ .82), whereas both US and CT were deﬁnitively
positive only about half the time in both populations (US:
46.7% versus 56.9%, P ¼ .22; CT: 41.2% versus 54.7%, P ¼ .24).
DISCUSSION
In the general U.S. population, gallstones affect approxi-
mately 20 million patients annually. Of such patients, 1% to
4% annually become symptomatic with biliary colic, and
acute cholecystitis eventually develops in about 20% of these
symptomatic patients if left untreated [13]. The incidence of
acute cholecystitis in our transplant cohort was much
higher, with acute cholecystitis diagnosed in the ﬁrst of year
of transplant in 32 of 644 patients (5.0%) who underwent
allogeneic HSCT. Patients who developed acute cholecystitis
suffered from higher 1-year mortality after transplant, and
3 patients with acute cholecystitis died as a direct result
of their gallbladder infections. We hypothesize that the
observed association between acute cholecystitis and 1-yearmortality may be related to the known correlation between
acalculous cholecystitis and critical illness [14] as well as the
need for TPN in patients with overall poorer nutritional and
performance status after transplant [15].
To our knowledge, this is the only study in the last 15
years to examine the incidence and risk factors for acute
cholecystitis with modern HSCT practices [9-12]. In our ﬁrst
case-control analysis, administration of TPN was the only
identiﬁed risk factor for developing acute cholecystitis in the
ﬁrst year after HSCT. Given the retrospective nature of the
study, we cannot prove causality with regard to the associ-
ation between TPN use and acute cholecystitis. However, the
observed temporal relationship between TPN use and diag-
nosis of acute cholecystitis is notable. Furthermore, hep-
atobiliary complications related to TPN have been widely
reported in the general population [16-22], and multiple
studies have demonstrated an increased risk of acute acal-
culous cholecystitis in patients receiving TPN [17-24]. The
propensity to develop acalculous cholecystitis is thought to
be related to TPN-induced bile stasis [19,22], which in turn
increases the concentration of lysophosphatidyl choline in
bile and promotes local injury of the gallbladder mucosa by
disrupting normal water transport across gallbladder mu-
cosa [25]. Although not recommended uniformly as pro-
phylaxis against nutritional depletion in HSCT patients, a
substantial proportion of HSCT patients ultimately require
TPN during the peritransplant period [15]. In HSCT patients
who require TPN, our data suggest that providers should
have a high index of suspicion for acute cholecystitis in the
setting of abdominal pain or abnormal liver function tests,
even after TPN has been discontinued.
In addition to TPN, prior studies have suggested that the
use of calcineurin inhibitors is associated with increased
rates of gallstones and acute cholecystitis, although this has
not been studied speciﬁcally in the HSCT population [26,27].
It is possible that the routine administration of calcineurin
inhibitors may have contributed to the high rate of chole-
cystitis observed in our cohort. However, because only 2
patients (those who underwent T celledepleted transplant)
did not receive a calcineurin inhibitor for GVHD prophylaxis,
we could not reliably evaluate calcineurin inhibitor use as a
risk factor for developing acute cholecystitis.
Our second case-control study demonstrated a trend to-
ward more equivocal US ﬁndings (as opposed to deﬁnitely
positive or negative) for acute gallbladder inﬂammation in
HSCT patients with acute cholecystitis compared with non-
transplant patients with this condition. In the general popu-
lation, a suspected diagnosis of acute cholecystitis can usually
be conﬁrmed with an abdominal US [28], as suggested in a
1994 systematic review reporting a sensitivity of 88% [29]. In
the HSCT population, however, our data suggest that US may
be less useful in making a prompt diagnosis of acute chole-
cystitis. The exact reasons for this discrepancy are unknown,
although we hypothesize that sonographic ﬁndings depen-
dent on the detection of acute inﬂammation, such as a posi-
tive “sonographic Murphy’s sign,” are less likely to be elicited
in the immunosuppressed transplant population. This may
result in the interpretation of fewer US studies as deﬁnitively
positive for acute cholecystitis. Similarly, we hypothesize that
transplant patients are also less likely to have US studies that
are deﬁnitively negative for acute cholecystitis, because these
patients often have subtle sonographic ﬁndings reminiscent
of cholecystitis that are actually related to other conditions,
such as gallbladder wall thickening and pericholecystic ﬂuid
secondary to hypoalbuminemia or volume overload.
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were deﬁnitively positive for acute cholecystitis in only
about half of the HSCT cases. Although this was no different
from the general population, the ability to deﬁnitively di-
agnose acute cholecystitis in a timely manner is likely more
important in the HSCT population, becasue morbidity and
mortality related to delayed diagnosis of intra-abdominal
infection may be substantially higher [30,31]. With regard
to nuclear imaging, HIDA scan was deﬁnitively positive for
acute cholecystitis in 80% of the HSCT patients in our study.
HIDA is indicated in the general population only when the
diagnosis of acute cholecystitis remains uncertain after US. In
the HSCT population, however, our data support the early use
of HIDA when acute cholecystitis is suspected, because both
US and CT are likely to yield equivocal results that may delay
life-saving recognition and treatment of acute cholecystitis.
There are several limitations to our study. It was retro-
spective, and although we attempted to be inclusive in our
screening for acute cholecystitis through ICD-9 codes, it is
possible that we underestimated the incidence of acute
cholecystitis with this method. In addition, because of the
retrospective nature of the study, US, CT, and HIDA scans
were read by several different radiologists, creating a po-
tential for interobserver variability. However, studies across
multiple centers have demonstrated consistently high
sensitivity and speciﬁcity of all 3 imaging modalities for the
detection of acute cholecystitis in the general population
[29,32-37], which suggests signiﬁcant disagreement among
radiologists at our institution is unlikely.
In conclusion, this study demonstrates that acute chole-
cystitis is a common complication of allogeneic HSCT, espe-
cially in patients who receive TPN, and is associated with
high 1-year mortality. Our data suggest that a high index of
suspicion and early use of HIDA scan are required to make a
prompt diagnosis of acute cholecystitis in HSCT patients.
Additional prospective studies are needed to determine
whether less TPN use decreases the incidence of acute
cholecystitis. Early use of HIDA scan should be considered
when there is clinical suspicion for this condition.
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